Shots:
- The Top 20 Radiopharma Companies of 2026, ranked by market capitalization, represent a powerful mix of global pharmaceutical leaders and agile innovators transforming radioligand therapies, alpha-emitters, and copper-based theranostics into pillars of modern oncology. What was once niche science is now redefining precision cancer care.
- Flagship therapies such as Lutathera, Pluvicto, Pylarify, Illuccix/Gozellix, Xofigo, and Milican anchor today’s market, while a strong pipeline wave targets high-value tumor markers, including PSMA, SSTR, PD-L1, HER2, FAP, GRPr, and uPAR broadening the scope of precision oncology and molecular imaging.
- The sector’s growth reflects this momentum. Radiopharmaceuticals are projected to expand from $14.2B in 2026 to $31.0B by 2032, reaching approximately $54.6B by 2040, at a CAGR of 10.1%. By market cap, Eli Lilly and Company leads the ranking, followed by Novartis and AstraZeneca, underscoring radiopharma’s rising strategic importance in the global oncology landscape.
20. Radiopharm Theranostics
Market Cap: 60.99M
Founded Year: 2021
Total Employees: 20
Headquarters: Sydney, Australia
Stock Exchange: ASX
- Radiopharm Theranostics, a clinical-stage biotech, is developing first-in-class radiopharmaceuticals across small molecules, peptides, nanobodies, and antibodies to target cancer beyond traditional PSMA and somatostatin-based approaches.
- Its pipeline includes RAD204, a PD-L1–targeting ¹⁷⁷Lu-labeled nanobody; RAD202, a HER2-targeted ¹⁷⁷Lu agent; RAD101, a FASN-targeted ¹⁸F imaging agent with strong brain metastasis uptake; and RAD301, a Ga-68 αvβ6 integrin–targeted peptide for pancreatic and other solid tumors, all progressing through ongoing clinical trials.
- Recently, RAD101 delivered compelling interim Phase IIb data in brain metastases, achieving MRI concordance in 92% of evaluable patients and demonstrating significant, selective tumor uptake on PET imaging.
19. DongWha Pharm
Market Cap: 123.52M
Founded Year: 1897
Total Employees: 830
Headquarters: Seoul, South Korea
Stock Exchange: KRX
- DongWha Pharm, Korea’s first established pharmaceutical company, has expanded from its historic drug development roots into nuclear medicine, developing radiotherapeutics that deliver localized therapeutic radiation.
- Its flagship radiopharmaceutical DW-166HC (Holmium-166 chitosan complex, marketed as Milican inj.) uses chitosan to retain ²⁶⁶Ho at the treatment site and is used in hepatocellular carcinoma therapy, with additional exploration in intra-tumoral and radiosynoviorthesis applications.
- In March 2025, DongWha Pharm signed an agreement with Takeda Korea for exclusive distribution of dexlansoprazole and lansoprazole in Korea, broadening its gastroenterology portfolio.
18. Oncoinvent
Market Cap: 192.81M
Founded Year: 2010
Total Employees: 40
Headquarters: Oslo, Norway
Stock Exchange: FRA
- Oncoinvent, a clinical-stage medical technology company, is developing alpha-particle therapies that deliver potent localized radiation to eradicate cancer cells while limiting exposure to nearby healthy tissue.
- Its lead radiotherapeutic, Radspherin, consists of biocompatible microparticles labeled with radium-224 and administered directly into body cavities such as the peritoneal space after surgery, with the goal of reducing recurrence in ovarian and other cancers at high risk of peritoneal spread.
- Oncoinvent presented positive 24-month follow-up data from its Phase I ovarian cancer study of Radspherin at ESGO 2026 in February 2026, highlighting durable local disease control and a favorable safety profile.
17. Monopar Therapeutics
Market Cap: 365.24M
Founded Year: 2014
Total Employees: 20
Headquarters: Illinois, United States
Stock Exchange: NASDAQ
- Monopar Therapeutics, a clinical-stage radiopharmaceutical biotech, is developing uPAR-targeted antibody radioconjugates designed to image and treat aggressive solid tumors by binding the urokinase plasminogen activator receptor on cancer cells.
- Its lead programs; MNPR-101-Zr (a zirconium-89 imaging agent), MNPR-101-Lu (a lutetium-177 therapeutic in a Phase Ia trial), and MNPR-101-Ac (an actinium-225 therapeutic in late preclinical development) all leverage a first-in-class uPAR-targeting platform aimed at maximizing tumor uptake while limiting healthy tissue exposure.
- On September 26, 2025, Monopar received FDA clearance to initiate a Phase I study of MNPR-101-Lu in advanced uPAR-positive tumors, evaluating safety, dosing, and early anti-tumor activity using its proprietary linker technology for improved stability and delivery.
16. Perspective Therapeutics
Market Cap: 576.4M
Founded Year: 2004
Total Employees: 140
Headquarters: Washington, United States
Stock Exchange: NYSE
- Perspective Therapeutics, a US-based radiopharmaceutical company, develops image-guided targeted alpha-particle therapies built on its proprietary Pb-212 platform, directing potent radiation to cancer cells via high-affinity targeting peptides.
- Its pipeline includes [²¹²Pb]VMT-α-NET for somatostatin receptor-positive neuroendocrine tumors, [²¹²Pb]VMT01 targeting MC1R in melanoma, and [²¹²Pb]PSV359 aimed at fibroblast activation protein-α (FAP-α) in solid tumors, each designed to unite imaging and therapy for highly selective tumor targeting.
- In January 2026, the company presented updated Phase I/IIa interim data for [²¹²Pb]VMT-α-NET at ASCO-GI 2026, demonstrating durable disease control and a favorable safety profile in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors.
15. Alpha Tau Medical
Market Cap: 676.95M
Founded Year: 2015
Total Employees: 130
Headquarters: Jerusalem, Israel
Stock Exchange: NASDAQ
- Alpha Tau Medical is developing an innovative form of alpha radiation therapy that delivers high-energy alpha particles directly into solid tumors, aiming for localized cancer cell destruction while limiting damage to surrounding healthy tissue.
- Its lead product, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), uses radioactive sources implanted within tumors that emit alpha particles, offering a potential option for difficult-to-treat solid cancers by exploiting the short, high-energy path length of alpha radiation.
- In January 2026, Alpha Tau Medical reported positive pancreatic cancer results ahead of the ASCO GI 2026 Symposium, noting an 81% disease control rate 87% when excluding the first two patients and signs of immune preservation.
14. Clarity Pharmaceuticals
Market Cap: 960.09M
Founded Year: 2010
Total Employees: 70
Headquarters: New South Wales, Australia
Stock Exchange: ASX
- Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical innovator, employs its proprietary SAR (sarcophagine) technology to develop copper-based theranostics that enable both imaging and treatment of cancers with exceptional specificity.
- Its pipeline showcases ⁶⁴/⁶⁷Cu-SAR-bisPSMA for PSMA-targeted prostate cancer imaging and therapy, SAR-BBN (bombesin-targeted) for GRPr-expressing tumors, and ⁶⁴Cu-SARTATE for neuroendocrine tumor imaging and potential therapy, all unified on a single platform pairing diagnostic and therapeutic isotopes.
- In October 2025, Clarity Pharmaceuticals and Nusano announced a supply agreement for Copper-67, securing reliable access to this essential theranostic isotope and fueling pipeline progression.
13. Eckert & Ziegler
Market Cap: 1.13B
Founded Year: 1997
Total Employees: 1,100
Headquarters: Berlin, Germany
Stock Exchange: ETR
- Eckert & Ziegler excels in radioisotope technology and radiopharmaceutical supply, delivering essential radionuclides and generator systems that power global diagnostic imaging and therapeutic advancements.
- Its lineup includes Yttriga (yttrium-90 chloride), GalliaPharm Ga-68 generators for PET imaging, non-carrier-added Lu-177 and Ac-225 for targeted therapies, plus Y-90 and I-123 for clinical and research use.
- In February 2026, Eckert & Ziegler and the Nuclear Physics Institute of the Czech Academy of Sciences ramped up Actinium-225 production in Řež and Braunschweig, achieving clinically relevant volumes to bolster global supply of this vital alpha emitter.
12. PeptiDream
Market Cap: 1.17B
Founded Year: 2006
Total Employees: 750
Headquarters: Indiana, United States
Stock Exchange: TYO
- PeptiDream, a peptide discovery and drug development specialist, harnesses its proprietary Peptide Discovery Platform to create targeted molecules, including radiopharmaceuticals for enhanced oncology diagnostics and treatments.
- Its radiopharma programs feature ⁶⁴Cu-ATSM, a hypoxia imaging agent to pinpoint low-oxygen tumor regions, and ¹⁷⁷Lu/⁶⁴Cu-PSMA I&T, dual-labeled PSMA agents for imaging (⁶⁴Cu) and therapy (¹⁷⁷Lu), demonstrating expertise in precision nuclear medicine peptides.
- In December 2025, PeptiDream gained FDA clearance to launch a Phase I study of 225Ac-PD-32766 and 64Cu-PD-32766 in kidney cancer patients.
11. Jubilant Pharmova
Market Cap: 1.52B
Founded Year: 1978
Total Employees: 5,500
Headquarters: Uttar Pradesh, India
Stock Exchange: NSE
- Jubilant Pharmova, a global life-sciences leader, excels in radiopharmacy and nuclear imaging solutions, delivering advanced radiopharmaceuticals and services to hospitals and imaging centers worldwide.
- Its radiopharma portfolio features Hicon and Ruby-Fill for cardiac and PET imaging, DraxImage tracers for SPECT diagnostics, and Smart-Fill kits that streamline preparation, all enhancing clinicians’ ability to visualize and diagnose diseases precisely.
- In November 2025, Jubilant Pharmova reported robust revenue growth, propelled primarily by its CDMO sterile injectables and radiopharmaceutical segments.
10. Telix Pharmaceuticals
Market Cap: 2.41B
Founded Year: 2015
Total Employees: 1,200
Headquarters: Melbourne, Australia
Stock Exchange: ASX
- Telix Pharmaceuticals, a biopharma dedicated to radiopharmaceuticals, crafts diagnostic imaging agents and therapeutic radioligand therapies that harness targeted radiation for superior cancer detection and treatment.
- Its pipeline centers on PSMA-targeted innovations like TLX591-CDx (Illuccix/Gozellix) for prostate cancer PET imaging and TLX591-Tx for therapy, plus agents for renal cancer (TLX250), gliomas (TLX101), and advanced radionuclides embodying a comprehensive theranostic approach.
- In January 2026, Telix announced FY25 revenues of approximately US$804M, driven largely by the US launch of Gozellix.
9. Lantheus Medical Imaging Inc. (Lantheus Holding)
Market Cap: 5B
Founded Year: 1956
Total Employees: 800
Headquarters: Massachusetts, United States
Stock Exchange: NASDAQ
- Lantheus Medical Imaging, part of Lantheus Holdings, pioneers radiopharmaceutical agents and diagnostics to help clinicians detect, treat, and monitor diseases through PET imaging, oncology, and precision medicine.
- Its robust portfolio includes top PET agents like Pylarify (PSMA PET for prostate cancer), neurology and oncology radiotracers, plus an advancing radiotherapeutic pipeline with PNT2003 and clinical-stage options like Octevy for neuroendocrine tumors.
- In 2025, Lantheus sealed strategic acquisitions of Evergreen Theragnostics and Life Molecular Imaging, enhancing radiopharmaceutical development, expanding diagnostics such as Neuraceq, and scaling manufacturing and R&D prowess.
8. BWXT Medical (BWX Technologies)
Market Cap: 18.95B
Founded Year: 1867
Total Employees: 8,700
Headquarters: Virginia, United States
Stock Exchange: NYSE
- BWXT Medical, a division of BWX Technologies, specializes in producing vital medical isotopes and radiopharmaceutical components, equipping hospitals and radiopharmacies for diagnostics and targeted therapies.
- It stands as a primary supplier of critical isotopes like Molybdenum-99 (Mo-99) the precursor to technetium-99m, which powers millions of imaging procedures annually while scaling up for emerging radionuclides in both diagnostic and therapeutic applications.
- In January 2026, BWXT highlighted advances in its technetium-99m generator program, fuelled by US-produced molybdenum, at an investor conference underscoring momentum in fortifying domestic radiopharmaceutical supply chains.
7. GE Healthcare
Market Cap: 38.25B
Founded Year: 1994
Total Employees: 54,000
Headquarters: Illinois, United States
Stock Exchange: NASDAQ
- GE HealthCare excels in medical imaging, diagnostics, and digital health technologies, fuelling precision medicine by integrating advanced imaging systems with radiopharmaceuticals for earlier, more reliable clinical decisions.
- Its Radiopharma business offers a wide array of PET and SPECT tracers, including FDG and PSMA-targeted agents backed by a vast global cyclotron network and radiopharmacy infrastructure for seamless production and distribution of diagnostic and theranostic isotopes.
- In February 2026, GE HealthCare introduced the ReadyFix fleet management solution to boost operational efficiency and ensure dependable patient care.
6. Bayer
Market Cap: 48.57B
Founded Year: 1863
Total Employees: 88,500
Headquarters: Leverkusen, Germany
Stock Exchange: ETR
- Bayer, a global life-sciences leader in healthcare, fuses advanced pharmaceuticals and diagnostics, including radiology and nuclear medicine to redefine disease diagnosis and treatment.
- Its radiopharmaceutical foundation includes Xofigo (radium-223 dichloride), a pioneering alpha therapy for metastatic prostate cancer, alongside an expanding pipeline of next-gen theranostics like 225Ac-PSMA-Trillium and 225Ac-GPC3, targeting prostate and liver cancers with high-potency alpha radiation.
- In April 2025, Bayer initiated a Phase I study for its novel actinium-225 radiopharmaceuticals in hepatocellular and metastatic prostate cancer.
5. Siemens Healthineers
Market Cap: 47.77B
Founded Year: 1876
Total Employees: 73,800
Headquarters: Bavaria, Germany
Stock Exchange: ETR
- Siemens Healthineers advances precision healthcare across diagnostics, molecular imaging, and theranostics, empowering clinicians to visualize, diagnose, and treat diseases with unmatched accuracy.
- Its Radiopharma business; merging expertise from PETNET Solutions and Advanced Accelerator Applications Molecular Imaging, stands as the world’s largest manufacturer and distributor of PET radiopharmaceuticals. The portfolio delivers essential tracers like FDG and PSMA-targeted agents to global imaging centers, while serving as a CDMO for innovative tracer development.
- Recently, Siemens Healthineers unified PETNET Solutions and AdAcAp Molecular Imaging under a single Radiopharma segment, expanding its global cyclotron network and boosting tracer production capacity in the US and Europe.
4. RayzeBio (BMS)
Market Cap: 124.43B
Founded Year: 1887
Total Employees: 32,500
Headquarters: New York, United States
Stock Exchange: NYSE
- RayzeBio, a clinical-stage radiopharmaceutical pioneer now under Bristol Myers Squibb, specializes in next-generation targeted radioligand therapies that pair precise targeting with powerful radioactive payloads.
- The pipeline features RYZ101, an alpha-emitting PSMA-targeted therapy for advanced prostate cancer; RYZ801, an enhanced PSMA agent with refined chemistry; and RYZ811, targeting alternative tumor markers, all engineered to deliver lethal radiation to cancer cells while protecting healthy tissue.
- In July 2025, BMS’s RayzeBio unit inaugurated a $160M radiopharma manufacturing plant in Indianapolis.
3. AstraZeneca
Market Cap: 315.53B
Founded Year: 1999
Total Employees: 94,300
Headquarters: Cambridge, London
Stock Exchange: LON
- AstraZeneca is bolstering its oncology portfolio with next-generation radioconjugates, merging targeted biology and potent radioactive payloads to precisely address challenging solid tumors.
- A key asset is AZD2068 (also known as FPI-2068), an EGFR/c-MET-targeting actinium-225 radioconjugate that delivers alpha radiation directly to tumor cells expressing these markers. It’s currently advancing in a Phase I study for advanced solid tumors across multiple indications.
- Recent pipeline updates highlight an ongoing Phase I dose-escalation trial for AZD2068, gathering safety, dosing, and early efficacy data with initial clinical results expected around 2027 as part of AstraZeneca’s expansive radioconjugate strategy.
2. Novartis
Market Cap: 351.59B
Founded Year: 1996
Total Employees: 75,300
Headquarters: Basel City, Switzerland
Stock Exchange: NYSE
- Novartis, a global biopharma powerhouse in oncology and radiopharmaceuticals, leads the charge in integrating targeted nuclear medicines into standard cancer care.
- Its established portfolio shines with Lutathera, a peptide receptor radionuclide therapy (PRRT) for specific neuroendocrine tumors, and Pluvicto, a PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer both precision tools that deliver therapeutic radiation straight to cancer cells.
- In January 2026, Zonsen PepLib Biotech (“PepLib”) revealed a worldwide exclusive license agreement with Novartis, including a $50M upfront payment, for an undisclosed peptide-based asset in radioligand therapies (RLTs).
1. Eli Lilly and Company
Market Cap: 964.13B
Founded Year: 1876
Total Employees: 50,000
Headquarters: Indiana, United States
Stock Exchange: NYSE
- Eli Lilly, a global leader in oncology and precision medicine, is steadily building momentum in its cancer portfolio through targeted investments in radiopharmaceuticals.
- Its pipeline features promising candidates like 225Ac-PSMA-62, an investigational alpha-emitting therapy for PSMA-positive prostate cancer, and PNT2001 both advancing radioligand therapies that precisely deliver radiation to tumor cells.
- In February 2025, the company deepened its innovation push with a strategic collaboration alongside AdvanCell to develop novel targeted alpha therapies (TATs) for cancer treatment.
Related Post: Top 20 Radiopharmaceutical Companies of 2025
Market Cap. Taken: 27 Feb 2026
